10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics (TXG), a leader in single cell and spatial biology, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.

The financial results will be accessible through a news release on the company's website before the conference call. Interested parties can access the live audio webcast through the 'Investors' section at investors.10xgenomics.com, with a replay available for at least 45 days following the event.

10x Genomics (TXG) has secured a significant legal victory against Parse Biosciences through a consent agreement entered on February 25, 2025, in the U.S. District Court for the District of Delaware. Parse agreed to a worldwide permanent injunction preventing them from making, using, or selling their planned ATAC and ATAC-Multiome Single Cell products.

Parse has admitted that 10x's ATAC-seq patents are valid, enforceable, and infringed by Parse's use of ATAC-seq methods and compositions. The agreement was reached one week before the scheduled trial. While this resolves the ATAC-related dispute, litigation regarding Parse's gene expression products continues, with additional patents under appeal. The March 2025 trial for remaining patent infringement claims has been stayed pending these appeals.

10x Genomics (TXG) announced new product innovations at the AGBT General Meeting to enhance its leadership in single cell and spatial biology. The company revealed significant advancements across its platforms, including:

For Chromium platform: New plate-based workflows for GEM-X Flex enabling analysis of 700+ samples per run, with capacity to recover 8 million cells per chip. The company is also launching 10x Cloud Analysis for Large Studies to manage extensive datasets.

For Visium platform: Planned additions include Visium HD 3' for high-resolution spatial profiling, Visium HD Cell Segmentation for morphology-guided analysis, and Visium HD XL for larger tissue sections.

For Xenium platform: Introduction of RNA+Protein Multiomics capability, allowing simultaneous detection of RNA and proteins on the same slide, featuring seven modular subpanels covering up to 28 protein targets.

10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 4, at 11:10 a.m. Eastern Time.

Investors and interested parties can access a live webcast of the discussion through the company's investor relations website at https://investors.10xgenomics.com/. The presentation will remain available for replay on the website for a minimum of 45 days following the event.

10x Genomics (TXG) reported Q4 and full year 2024 financial results, showing revenue declines and continued operating losses. Q4 revenue decreased 10% to $165.0 million, while full-year revenue fell 1% to $610.8 million. The company's gross margin improved to 67% in Q4 and 68% for the full year.

Operating expenses decreased 6% to $160.8 million in Q4, with an operating loss of $49.8 million. For the full year, operating loss improved to $194.6 million from $265.3 million in 2023. The company ended 2024 with $393.4 million in cash and marketable securities.

Looking ahead, 10x Genomics provided 2025 revenue guidance of $610-630 million, projecting 0-3% growth. The company expects double-digit growth in both Chromium reactions and spatial revenue at the midpoint of guidance.

Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project, collaborating with 10x Genomics and Ultima Genomics to create an unprecedented one billion cell dataset for advancing AI in biology. The project aims to enhance understanding of cellular behavior and gene function through large-scale data generation.

The initiative will utilize 10x Genomics' Chromium GEM-X technology for single-cell analysis and Ultima Genomics' UG 100™ platform for high-throughput sequencing. The dataset will include organisms such as mouse, zebrafish, and primary human cell models, focusing on gene regulation and function across organisms.

CZI plans to make all results open source and freely available to scientists worldwide. The project will leverage CZI's computing system, one of the largest dedicated to nonprofit life sciences research, to train new virtual cell models and derive insights from the vast dataset.

10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has announced it will release its fourth quarter and full year 2024 financial results after market close on February 12, 2025. The company will hold a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.

The financial results will be available on the company's website before the conference call. Investors can access the live webcast through the 'Investors' section of 10x Genomics' website, where it will remain available for replay for at least 45 days following the event.

10x Genomics (TXG) has announced preliminary, unaudited results for Q4 and full year 2024. The company reported Q4 2024 revenue of ~$165.0 million, showing 9% sequential growth but a 10% year-over-year decrease. Full-year 2024 revenue reached ~$610.8 million, representing a 1% decrease from 2023.

Q4 breakdown shows Instruments revenue at $24.4 million (28% sequential growth, -37% YoY), Consumables revenue at $133.5 million (6% sequential growth, -5% YoY), and Services revenue at $7.1 million (12% sequential growth, +35% YoY). The company's cumulative instrument installations exceeded 7,000 units, including over 5,800 Chromium, 800 Visium, and 400 Xenium instruments. Cash position stood at approximately $393 million as of December 31, 2024.

10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, at 7:30 a.m. Pacific Time.

The presentation will take the format of a fireside chat and will be accessible via live webcast through the 'Investors' section of 10x Genomics' website. For those unable to attend live, the webcast recording will remain available for replay for a minimum of 30 days following the event.